BRUKER CORPORATION Equity Method Investment, Other than Temporary Impairment
BRUKER CORPORATION (BRKR) reported Equity Method Investment, Other than Temporary Impairment of $4.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment · last filed 2026-08-05
- BRUKER CORPORATION equity method investment, other than temporary impairment for the quarter ending 2026-06-30 was $4.10M.
- BRUKER CORPORATION equity method investment, other than temporary impairment for the quarter ending 2026-03-31 was $600.00K, a 68.42% decline year-over-year.
- BRUKER CORPORATION equity method investment, other than temporary impairment for the quarter ending 2025-12-31 was $2.20M.
- BRUKER CORPORATION equity method investment, other than temporary impairment for the quarter ending 2025-09-30 was $15.90M, a 261.36% increase year-over-year.
- BRUKER CORPORATION equity method investment, other than temporary impairment for fiscal 2025 was $20.00M, a 18.70% decline from fiscal 2024.
- BRUKER CORPORATION equity method investment, other than temporary impairment for fiscal 2024 was $24.60M, a 35.16% increase from fiscal 2023.
- BRUKER CORPORATION equity method investment, other than temporary impairment for fiscal 2023 was $18.20M.
- BRUKER CORPORATION equity method investment, other than temporary impairment for fiscal 2022 was $0.00.
| Period end | Equity Method Investment, Other than Temporary Impairment 3 month | Equity Method Investment, Other than Temporary Impairment 6 month | Equity Method Investment, Other than Temporary Impairment 9 month | Equity Method Investment, Other than Temporary Impairment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.10M 10-Q · filed 2026-08-05 | $4.70M 10-Q · filed 2026-08-05 | $6.90M derived: sum of 3 quarters · filed 2026-08-05 | $22.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $600.00K 10-Q · filed 2026-05-07 | $2.80M derived: sum of 2 quarters · filed 2026-05-07 | $18.70M derived: sum of 3 quarters · filed 2026-05-07 | $18.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $18.10M derived: sum of 2 quarters · filed 2026-02-27 | $18.10M derived: sum of 3 quarters · filed 2026-08-05 | $20.00M 10-K · filed 2026-02-27 |
| 2025-09-30 | $15.90M 10-Q · filed 2025-11-05 | $15.90M derived: sum of 2 quarters · filed 2026-08-05 | $17.80M 10-Q · filed 2025-11-05 | $17.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $1.90M 10-Q · filed 2026-08-05 | $1.90M derived: sum of 3 quarters · filed 2026-08-05 | $6.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.90M 10-Q · filed 2026-05-07 | $1.90M derived: sum of 2 quarters · filed 2026-05-07 | $6.30M derived: sum of 3 quarters · filed 2026-05-07 | $26.50M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $4.40M derived: sum of 2 quarters · filed 2026-02-27 | $24.60M derived: sum of 3 quarters · filed 2026-02-27 | $24.60M 10-K · filed 2026-02-27 |
| 2024-09-30 | $4.40M 10-Q · filed 2025-11-05 | $24.60M derived: sum of 2 quarters · filed 2025-11-05 | $24.60M 10-Q · filed 2025-11-05 | $24.50M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $20.20M 10-Q · filed 2025-08-06 | $20.20M 10-Q · filed 2025-08-06 | $20.10M derived: sum of 3 quarters · filed 2026-02-27 | $20.10M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | -$100.00K derived: sum of 2 quarters · filed 2026-02-27 | -$100.00K derived: sum of 3 quarters · filed 2026-02-27 | $11.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$100.00K derived: sum of 2 quarters · filed 2026-02-27 | $11.30M derived: sum of 3 quarters · filed 2026-02-27 | $18.20M 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $11.40M derived: sum of 2 quarters · filed 2024-11-07 | $18.30M 10-Q · filed 2024-11-07 | $18.30M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $11.40M 10-Q · filed 2024-08-09 | $18.30M 10-Q · filed 2024-08-09 | $18.30M derived: sum of 3 quarters · filed 2025-03-03 | $18.30M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $6.90M 10-Q · filed 2024-05-10 | $6.90M derived: sum of 2 quarters · filed 2025-03-03 | $6.90M derived: sum of 3 quarters · filed 2025-03-03 | $6.90M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |